Therapeutic response and safety of radioligand therapy with 177 Lu-PSMA-617 in metastatic castration-resistant prostate cancer patients.
Wardah AshfaqKhurram RehmanAbubaker ShahidMuhammad Numair YounisPublished in: Medical oncology (Northwood, London, England) (2024)
Prostate cancer is one of the most common cancers and leading cause of death due to cancer across the globe. This persuaded researchers to devise innovative treatment modalities that may prove effective, safe, and demonstrate better outcomes in terms of patient morbidity and survival. The advancement in theranostics such as lutetium-177 ( 177 Lu)-PSMA-617 radioligand therapies can target prostate cancer cells causing negligible or no damage to most of the normal tissues in patients. It has been proven to effectively improve the quality of life and progression-free survival. In this study, stage IV metastatic castration-resistant prostate cancer patients were treated with 177 Lu-PSMA-617, and the therapeutic response and safety of 177 Lu-PSMA-617 radioligand therapy were evaluated six months after the treatment. Additionally, molecular docking studies were also conducted to find the possible mechanism at the molecular level that causes the effectiveness of 177 Lu-PSMA-617 in prostate cancer.
Keyphrases
- prostate cancer
- end stage renal disease
- pet ct
- newly diagnosed
- chronic kidney disease
- ejection fraction
- pet imaging
- peritoneal dialysis
- prognostic factors
- gene expression
- oxidative stress
- type diabetes
- stem cells
- young adults
- metabolic syndrome
- patient reported outcomes
- computed tomography
- radical prostatectomy
- mesenchymal stem cells
- weight loss
- case report
- skeletal muscle